Fetal infections with bovine viral diarrhea virus (BVDV) may result in infertility, abortions, stillbirths, developmental anomalies, and weak calves. 1 Infection of the fetus from 58 to 120 days of gestation may create persistently infected (PI) calves that shed the virus continuously and perpetuate the herd infection. 10, 11 In beef herds, calf losses and PI calves have a significant impact on herd productivity. 14 Vaccination with modified live virus (MLV) BVDV vaccines is commonly practiced in Wyoming beef herds to prevent reproductive losses due to BVDV infection. However, the majority of BVDV isolates obtained at the Wyoming State Veterinary Laboratory (WSVL) are from vaccinated herds. For example, in 1996 BVDV was isolated from 30 herds for which vaccination histories were available. Twenty-four herds had a history of BVDV vaccination and 6 were not vaccinated for BVDV. BVDV-associated diseases in beef herds vaccinated with inactivated BVDV vaccines have been reported. 8, 9 Here, we describe the isolation of type 2 BVDV-associated reproductive losses in beef herds where the cows were vaccinated with a type 1a MLV-BVDV vaccine a and the use of serology to detect BVDV infection retrospectively.
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Fetal infections with bovine viral diarrhea virus (BVDV) may result in infertility, abortions, stillbirths, developmental anomalies, and weak calves. 1 Infection of the fetus from 58 to 120 days of gestation may create persistently infected (PI) calves that shed the virus continuously and perpetuate the herd infection. 10, 11 In beef herds, calf losses and PI calves have a significant impact on herd productivity. 14 Vaccination with modified live virus (MLV) BVDV vaccines is commonly practiced in Wyoming beef herds to prevent reproductive losses due to BVDV infection. However, the majority of BVDV isolates obtained at the Wyoming State Veterinary Laboratory (WSVL) are from vaccinated herds. For example, in 1996 BVDV was isolated from 30 herds for which vaccination histories were available. Twenty-four herds had a history of BVDV vaccination and 6 were not vaccinated for BVDV. BVDV-associated diseases in beef herds vaccinated with inactivated BVDV vaccines have been reported. 8, 9 Here, we describe the isolation of type 2 BVDV-associated reproductive losses in beef herds where the cows were vaccinated with a type 1a MLV-BVDV vaccine a and the use of serology to detect BVDV infection retrospectively.
In the fall of 1995, 28 cow-calf herds located in Weston County, Wyoming, had unusually high infertility rates followed by abortions, stillbirths, and weak calves in the spring of 1996. In 9 herds, the dams were vaccinated with the type 1a MLV-BVDV vaccine. a Gross findings in aborted fetuses and neonatal calves included hemorrhage in the subcutaneous tissues of lower extremities, muscle, and myocardium and on the serosal surfaces of multiple organs, serosanguinous fluid in thorax and abdominal cavities, and lens opacities. Fourteen animal tissue samples from 13 ranches were submitted. These animals included 5 fetuses, 6 neonatal calves, 2 calves 1 and 5 months of age, and a yearling steer. Two of the fetuses were autolyzed, and the remaining tissues were collected 15 minutes to 18 hours postmortem.
Virus isolations (VI) were performed using 10% tissue homogenates in Bovarnick's solution (0.218 M sucrose, 3 mM KH 2 PO 4 , 7.2 mM K 2 HPO 4 , 5.4 mM L-glutamic acid, 500 mg/liter streptomycin, 0.001% phenol red, pH 7.2) clarified by centrifugation and used to inoculate primary bovine embryonic testicle (BeT) cells previously tested and found negative for adventitial BVDV infection. Inoculated BeT cells were passed twice and stained for BVDV using monoclonal antibody 20.10.6 b and fluorescein isothiocyanate-conjugated goat anti-mouse antibody c as previously described. 18 Blood samples from calves were collected from the jugular vein into heparinized tubes. d Plasma samples were tested for BVDV using a microtiter BVDV isolation and immunoperoxidase monolayer staining procedure (IPMA). 13, 18 Serum and plasma samples were heated in a 56 C waterbath for 30 minutes. Two serum neutralization (SN) assays were performed on each serum or plasma sample using cytopathic (cp) viruses NADL-BVDV (type 1a) or B3491 (type 2). 4 NADL-BVDV is the virus in the MLV-BVDV vaccine, a and B3491 is 1 of the cp BVDVs isolated from these herds.
Five BVDVs were isolated from the 14 tissue samples. Three isolates of noncytopathic type 2 BVDV were made from an aborted fetus (B1846) and neonatal calves (B2222, B3296). A cp type 2 BVDV (B3491) was isolated from a yearling steer with pneumonia, and cp type 1a BVDV (B8361) was recovered from the lungs of a 5-month-old calf. Type 2 BVDVs B3296 (ranch A) and B2222 (ranch B) were from calves whose dams were vaccinated with a type 1a MLV-BVDV vaccine. a Genotypes were determined by reverse transcription polymerase chain reaction (PCR) (J. Ridpath and S. Bolin, personal communication). 12 Bacteria were cultured for 12 cases, and chlamydial isolation and histopathologic examinations were performed for 7 cases. Significant bacteriologic isolates, histopathologic changes, or chlamydia were not found. Toxicologic examination for nitrates in 1 fetus was negative.
Records of calf mortality were available from 2 ranches (A and B) where BVDV was isolated. Of 250 calves born on ranch A, 20 died in the neonatal period and 9 others showed signs of respiratory disease and died later that summer. Total calf mortality, from birth to weaning, on ranch A was 11.6% (29/250). Ranch B had a birth-to-weaning calf mortality rate of 11.2% (38/340). A third ranch, where B1846 was isolated, had an estimated 25% total loss due to infertility and calf mortality. Information on the BVDV vaccine used, infertility, and calf mortality was not available from the ranch where the fifth isolate, B3491, was obtained. The diagnosis of BVDV infection in these 4 herds was made on the basis of BVDV isolated from affected animals.
Ranch C was 1 of 13 from which tissues were submitted; however, virus was not isolated and no diagnosis was made. The cows and heifers were vaccinated with the type 1a MLV-BVDV vaccine a in May 1995 prior to breeding. Ranch C had unexpectedly high infertility in the fall of 1995, and 9.5% of heifers and cows (37/391) were determined not to be pregnant at that time. Calving took place from March through June 1996, at which time 7.9% of neonatal calves died (28/354). Necropsies were performed on 4 of the 28 dead calves, and ecchymotic hemorrhages were observed on multiple organs of each calf. Tissues from 1 calf were positive for BVDV by fluorescent antibody stain. Blood was collected from all surviving calves at ranch C in October at weaning when they were 4-7 months of age. Serum samples drawn from 18 heifers that gave birth to stillborn or weak calves at ranch C were assayed for SN titers.
Of the surviving calves on ranch C, none were viremic and 9.2% (30 of 326) had SN titers to type 2 BVDV of Ն1: 1,024. For each calf, the SN titers to type 2 BVDV were 4fold or greater than those to type 1a BVDV, suggesting prior exposure to type 2 BVDV. Fifteen of 18 heifers with weak or stillborn calves had SN titers of Ն1:1,024 to type 2 BVDV. The SN titers to type 1a BVDV were greater than or equal to the type 2 SN titers in 8 heifers, suggesting a strong anamnestic response to the vaccine virus.
A potential source of BVDV infection could not be identified by the ranch C owner; however, a subset of his cows was pastured with other herds during the breeding season from June 1 to September 15, 1995. This pasture was adjacent to ranches A and B and another ranch, D. The cows returned to ranch C in September where they were pastured next to the affected heifers.
An additional ranch, ranch D, had a history of decreased calving rate in the spring of 1996. Cows and heifers at ranch D also were vaccinated with the type 1a MLV-BVDV vaccine a in May 1995 prior to breeding. Two herds from ranch D (D1 and D2) were examined for pregnancy on September 15 and October 8, 1995, and only pregnant cows were retained. Ranch D is adjacent to ranches A and B where type 2 BVDVs were isolated. Following pregnancy examination, herd D1 cows accidentally intermingled with a neighboring herd from mid-October until the end of November. Calving occurred from March through June 1996, and 11% of the cows in herd D1 (27/246) did not deliver calves. Aborted fetuses were not available for testing.
Surviving D1 calves were examined retrospectively for serologic evidence of exposure to type 2 BVDV. Calves from herd D1 were sampled in October 1996 at 4-7 months of age, and 3.1% (8/255) had SN titers of Ն1:1,024 to type 2 BVDV. All 8 calves had titers to type 2 BVDV that were Ն4-fold higher than those to type 1a. In contrast, herd D2 was isolated from other cattle throughout 1995. One hundred percent of the cows in herd D2 (492/492) produced live calves. There were 2 neonatal deaths in this group, leaving 490 calves available for testing. Two calves in herd D2 had SN titers of 1:1,024 to type 2 BVDV, and no calves in this group had SN titers of Ͼ1:1,024.
For comparison, 106 calves at the University of Wyoming Beef Unit (UW) were sampled on November 1, 1996, at 7-9.5 months of age. Every animal in the UW herd has been tested for BVDV viremia since 1994, and all dead cattle have been submitted to the WSVL for necropsy and diagnostic testing. BVDV has not been isolated from any animal since testing began. In March and April of 1995 and 1996, the UW heifers and cows were immunized with the type 1a MLV-BVDV vaccine. a The UW herd was bred by artificial insemination from April 15 through July 1, 1995, and administered an inactivated viral vaccine in October 1995. None of the calves from the UW herd had SN titers Ն1:256 to either type 1a or type 2 BVDV at weaning.
Data on SN titers to type 2 BVDV from ranch C, herds D1 and D2 from ranch D, and the UW herd were categorized into 3 groups, low (Յ1:16), medium (Ն1:32 and Յ1:512), and high (Ն1:1,024), resulting in a 4 ϫ 3 contingency table (Table 1) . A chi-square test was performed to assess whether the distribution across the low, medium, and high SN titer groups was the same for the 4 herds examined. The resulting test statistic had a value of 152.314, with 6 degrees of freedom and a P value of Ͻ0.0001. Thus, the distribution of SN titers to type 2 BVDV was different across the 4 herds. To determine whether the difference was related to history of exposure, the contingency table was then partitioned to compare herds D1 and D2 from ranch D. The vaccination and management of these 2 herds was the same, and herd D1 only differed in its history of exposure to other cattle. In this case, the chi-square statistic had a value of 27.656. Because multiple tests were performed, the P value for this statistic from the partitioned table was calculated using a chi-square test with 6 degrees of freedom. The resulting P value of Ͻ0.0001 indicates a significant difference between the distribution of SN titers for the exposed D1 and unexposed D2 herds of ranch D. 5 Calf mortality of 9.6-16.6% occurred between birth and weaning in the herds examined. The extent of calf losses experienced in these herds exceeded the average calf mortality of 4.8% reported for range beef herds, 15 4-7% reported for a beef herd with endemic BVDV infection, 14 and 1.4% in an uninfected beef herd (UW). The losses were associated with the isolation of type 2 BVDV and high SN titers to type 2 BVDV, suggesting an episode of epidemic BVDVassociated disease following exposure to a type 2 BVDV.
In these investigations, evidence of BVDV infection in reproductive disease outbreaks was dependent on serologic findings and would have been missed if the diagnosis depended solely on demonstrating the virus in tissues or blood by VI, IPMA, or PCR. Ranches C and D represent situations in which viremic calves were not detected at the time of the investigation, unlike previously reported cases of BVDV in-fection. 8, 9, 14 Infection of pregnant cows with BVDV after 125 days of gestation can result in reproductive losses, but PI animals may not be generated. 10 In the case of herd D1 at ranch D, the timing of exposure during midgestation may account for the lack of PI calves detected in this cohort.
Examination of SN titers in the cow is of little value in the diagnosis of BVDV-related abortions because infection and seroconversion may have occurred months prior to the abortion. 2, 7 BVDV serology is further complicated by the widespread use of BVDV vaccines and universal SN titers in adult cattle. However, serologic examination of weaned calves can be useful in distinguishing exposure to BVDV, even in vaccinated herds. 17 BVDV infection of fetuses after 125 days of gestation and of calves results in precolostral antibody titers to specific BVDV antigens. 10 Because natural exposure to BVDV results in lifelong antibody levels, 6 SN titers of calves infected with BVDV remain elevated at weaning. 17 These titers are masked by maternal antibody levels until such time as those levels have declined. In the aftermath of an abortion outbreak, where BVDV is suspected but not isolated, evaluating SN titers in surviving calves at the time of weaning may make retrospective diagnosis possible.
High SN titers to type 2 BVDV (1:1,024) from ranch C and ranch D calves illustrates the importance of performing serology for the relevant BVDV genotype. 7 The viruses used for SN testing in this investigation were the type 1a strain (NADL) used in the MLV-BVDV vaccine and a cp type 2 BVDV isolate from a disease outbreak in the same geographic area. Calves were identified that had high SN titers (Ն1:1,024) to type 2 BVDV. These titers were Ն4-fold higher than SN titers to type 1a BVDV in the same individuals, suggesting infection with type 2 BVDV. Given the historical information, these calves would have been exposed to BVDV in utero.
There are special circumstances pertaining to range beef cattle management where the diagnosis of BVDV may be missed. Access to range beef cattle usually is limited to branding and weaning. Maternal antibodies in serum of calves 1-3 months of age (at branding) may interfere with the detection of viremic calves by VI and IPMA. 3 PI calves have low survivorship and may no longer be alive if testing is delayed until weaning. 1 If abortions occur while the cows are on pasture, predation and large pasture size make recovery of fetuses unlikely.
Immunization with BVDV vaccines is common practice in beef herds. Expectations are that vaccination will prevent fetal and calf mortality. Presently, regulations do not require vaccine testing for fetal protection. 16 The cases described include herds immunized with a type 1a MLV-BVDV vaccine. a The isolation of type 2 BVDV and association of reproductive losses with high SN titers to type 2 BVDV in calves at weaning suggest that maternal immunization does not protect fetuses from infection with antigenically distinct strains of BVDV. BVDV infection should not be overlooked as a possible cause of reproductive losses in vaccinated herds.
